肺癌药物市场：依疾病、分子、通路划分 - 全球预测 2023-2030

预计2023年全球肺癌药物市场将大幅成长247.6亿美元，年复合成长率为9.04%，到2030年将达到454.5亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球肺癌治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球肺癌药物市场规模及预测如何？

2.在预测期内，COVID-19对全球肺癌治疗药物市场的阻碍因素与影响为何？

3.在预测期内，全球肺癌药物市场需要投资哪些产品/细分市场/应用/领域？

4.贵公司在全球肺癌药物市场的竞争策略为何？

5.全球肺癌药物市场的技术趋势和法律规范是什么？

6.全球肺癌药物市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入肺癌药物全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 肺癌病例和发生率增加
    • 消费者对标靶治疗的需求不断增长
    • 世界各地的吸烟者人数正在增加
    • 政府对肺癌控制的有利支持
  • 抑制因素
    • 肺癌药物的副作用
  • 机会
    • 正在进行的肺癌治疗研究活动
    • 新药领域技术进步
  • 任务
    • 生物製剂和标靶治疗的可用性以及肺癌治疗的高成本
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章肺癌药物市场：依疾病分类

• 非小细胞肺癌
• 小细胞肺癌

第7章依分子分類的肺癌治疗药物市场

• 生物製品
• 低分子

第8章肺癌治疗药物市场：依分销管道分类

• 离线
• 在线的

第9章美洲肺癌药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第10章亚太肺癌药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第11章欧洲、中东和非洲肺癌药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第12章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

• 讨论指南
• 关于许可证和定价

The Global Lung Cancer Drugs Market is forecasted to grow significantly, with a projected USD 24.76 billion in 2023 at a CAGR of 9.04% and expected to reach a staggering USD 45.45 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Lung Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Lung Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease, market is studied across Non-Small Cell Lung Cancer and Small Cell Lung cancer. The Non-Small Cell Lung Cancer is projected to witness significant market share during forecast period.

Based on Molecule, market is studied across Biologics and Small Molecules. The Small Molecules is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Lung Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Lung Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Lung Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Lung Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Lung Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Lung Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Lung Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Lung Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Lung Cancer Drugs Market, by Disease, 2022 vs 2030
• 4.3. Lung Cancer Drugs Market, by Molecule, 2022 vs 2030
• 4.4. Lung Cancer Drugs Market, by Distribution Channel, 2022 vs 2030
• 4.5. Lung Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising cases and incidences of lung cancer
    • 5.1.1.2. Growing demand for the targeted therapies by consumers
    • 5.1.1.3. Increase in the number of smokers across the globe
    • 5.1.1.4. Favorable government support to control lung cancer
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects of lung cancer drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research activities in the lung cancer treatments
    • 5.1.3.2. Technological advancement in the fields of novel drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of biologics & targeted therapies and high cost of lung cancer treatments
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Lung Cancer Drugs Market, by Disease

• 6.1. Introduction
• 6.2. Non-Small Cell Lung Cancer
• 6.3. Small Cell Lung cancer

7. Lung Cancer Drugs Market, by Molecule

• 7.1. Introduction
• 7.2. Biologics
• 7.3. Small Molecules

8. Lung Cancer Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Offline
• 8.3. Online

9. Americas Lung Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Lung Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Lung Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. LUNG CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. LUNG CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
• FIGURE 5. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2022 VS 2030 (%)
• FIGURE 6. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. LUNG CANCER DRUGS MARKET DYNAMICS
• FIGURE 9. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. LUNG CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 5. LUNG CANCER DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 8. LUNG CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 11. LUNG CANCER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. LUNG CANCER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 24. CANADA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 25. CANADA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 38. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 39. AUSTRALIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 41. CHINA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 42. CHINA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 44. INDIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 45. INDIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 47. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 48. INDONESIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 50. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 51. JAPAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 54. MALAYSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 56. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 57. PHILIPPINES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 59. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 60. SINGAPORE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 62. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 63. SOUTH KOREA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 65. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 66. TAIWAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 68. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 69. THAILAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 71. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 72. VIETNAM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 74. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 79. DENMARK LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 81. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 82. EGYPT LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 84. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 85. FINLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 87. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 88. FRANCE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 90. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 91. GERMANY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 93. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 94. ISRAEL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 96. ITALY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 97. ITALY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 99. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 100. NETHERLANDS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 103. NIGERIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 105. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 106. NORWAY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 108. POLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 109. POLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 111. QATAR LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 112. QATAR LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 114. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 115. RUSSIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 117. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 118. SAUDI ARABIA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 120. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 123. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 124. SPAIN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 126. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 127. SWEDEN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 129. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 130. SWITZERLAND LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 132. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 133. TURKEY LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 135. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 136. UNITED ARAB EMIRATES LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 138. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED KINGDOM LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 141. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 142. LUNG CANCER DRUGS MARKET LICENSE & PRICING